Alzheimer’s
Scientists identify key role of divisive Alzheimer’s protein
February 8, 2017Research and Development Alzheimer's
Researchers from the Stark Neurosciences Research Institute at Indiana University have claimed to have finally identified the purpose of an …
Benzodiazepines increase stroke risk in Alzheimer’s patients, study finds
January 16, 2017Research and Development, Sales and Marketing Alzheimer's, Alzheimers, benzodiazepines
Benzodiazepines and similar drugs could increase the risk of strokes in Alzheimer’s patients by as much as 20% according to …
First human trial of tau-targeting Alzheimer’s vaccine shows promise
December 15, 2016Medical Communications, Research and Development Alzheimer's
The latest in a succession of promising announcements surrounding Alzheimer’s R&D, researchers at the Karolinska Institutet in Stockholm, Sweden have …
Flickering LEDs could light the way for new Alzheimer’s treatment
December 8, 2016Medical Communications, Research and Development Alzheimer's, Cognito therapeutics, mice
Research to find a potential new treatment for Alzheimer’s was hit a blow late last month, as Eli Lilly discontinued …
New Alzheimer’s research edges closer to treatment & prevention
December 7, 2016Research and Development Alzheimer's
A new study has shed light on the possible prevention and treatment of Alzheimer’s disease thanks to findings centred on …
New molecular-binding technique promises accelerated drug development
December 5, 2016Research and Development, Sales and Marketing Alzheimer's, Cancer, Indiana University-Purdue University Indianapolis
Researchers at the School of Science at Indiana University-Purdue University Indianapolis (IUPUI) have claimed to have designed a new molecular …
Lilly forced to abandon Alzheimer’s drug after failed trial
November 24, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, Alzheimer's disease, Eli Lilly
Eli Lilly announced that the results of its ‘Expedition 3’ trial for an experimental Alzheimer’s disease drug meant that they would …
MSD’s Alzheimer’s study could break new ground for treatment
November 3, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, MSD, clinical trials
MSD, known as Merck in North America, has published results of a Phase I trial of verubecestat. The drug is …
Alzheimer’s drug failure sends Lundbeck’s shares crashing
September 23, 2016Medical Communications, Research and Development Alzheimer's, Lundbeck, cultural failings
Lundbeck’s experimental idalopirdine has failed to meet its primary endpoint in its first Phase III trial in the treatment of …
FDA fast track designation for Biogen’s investigational Alzheimer’s treatment
September 2, 2016Medical Communications, Research and Development Alzheimer's, Alzheimer’s, Biogen, FDA, aducanumab, fast track
Biogen has announced that its investigational Alzheimer’s disease treatment aducanumab has been granted fast track designation by the FDA. The …
LMTX fails Phase III trial, monotherapy benefits seen
July 28, 2016Research and Development Alzheimer's, LMTX, TauRX, phase III, phase III failure
TauRX Therapeutics has reported Phase III clinical trial results for its novel tau aggregation inhibitor LMTX. The results indicated that …
Biogen Alzheimer’s treatment accepted into EMA’s PRIME scheme
June 2, 2016Research and Development, Sales and Marketing Alzheimer's, Biogen, EMA, PRIME, accelerated approval
Biogen (NASDAQ: BIIB) has announced that the European Medicines Agency (EMA) has accepted its investigational treatment for Alzheimer’s disease, aducanumab, …
AstraZeneca and Eli Lilly to enter Phase III on Alzheimer’s clinical trials
April 8, 2016Medical Communications AZD3293, Alzheimer's, Alzheimers, AstraZeneca, amaranth, clinical trial, lilly, phase III
AstraZeneca and Eli Lilly have announced the continuation of their clinical trial for people with early Alzheimer’s disease into Phase …
Allergan to partner with Heptares in Alzheimer’s disease collaboration
April 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Alzheimer's, Heptares, R&D, collaboration, commercialisation, h1, h4, neurological disorders, partnership, research and development, treatments
Bouncing back quickly from the collapse of the collapse of the Pfizer inversion deal, Allergan (NYSE:AGN) has announced a new …
South Florida Uni begins £875,000 dementia drug research programme
March 1, 2016Manufacturing and Production, Research and Development Alzheimer's
Funding from a consortium worth £875,000 pounds has helped kick start a new dementia drug research program at the University …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
